Details for Patent: 10,730,876

Which drugs does patent 10,730,876 protect, and when does it expire?

Patent 10,730,876 protects TURALIO and is included in one NDA.

This patent has fifty-three patent family members in twenty-eight countries.

Summary for Patent: 10,730,876

Title:	Synthesis of a compound that modulates kinases
Abstract:	The present disclosure provides processes for the preparation of a compound of formula I: ##STR00001## or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
Inventor(s):	Ibrahim; Prabha N. (Mountain View, CA), Jin; Masayoshi (Tokyo, JP), Matsuura; Shinji (Tokyo, JP)
Assignee:	Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP)
Application Number:	16/510,617
Patent Claim Types: see list of patent claims	Compound; Process;

Drugs Protected by US Patent 10,730,876

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	No				Y
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		DISCN	Yes	No				Y

International Family Members for US Patent 10,730,876

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016258027
Brazil	112017023490
Brazil	112017023540